4th Dec 2015 09:04
LONDON (Alliance News) - Regenerative medical devices maker Tissue Regenix Group PLC on Friday said two patients at a hospital in Barcelona have received the first OrthoPure XT decellularised tendons using the company's dCELL technology.
The patients received the tendons as part of a clinical safety study being conducted with a view to securing CE approval to enable the launch of the OrthoPure XT products in the European Union by 2017.
The patients were given the OrthoPure tendons to replace damaged anterior cruciate ligament, allowing a like-for-like repair of the damaged area.
Tissue Regenix also said it hopes the recruitment of the first 20 patients for the clinical trial of its OrthoPure XM meniscus product will be completed early in the first quarter of 2016. This would keep the company on track for CE mark submission of the product in the second half of 2016.
Shares in Tissue Regenix were up 4.1% on Friday morning to 15.09 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Tissue Regenix Group